Novel Phenethylamines and Their Potential Interactions With Prescription Drugs: A Systematic Critical Review.
Therapeutic drug monitoring April 1, 2020 Funda Inan, Tibor M Brunt, Ramon R Contrucci et al. 9 citations
The novel phenethylamines 4-fluoroamphetamine (4-FA) and 2,5-dimethoxy-4-bromophenethylamine (2C-B) are among the ten most used new psychoactive substances among high-risk users, and their use is also common in people with depression, ADHD, and those engaging in risky sexual behavior. A systematic review of literature on interactions between these phenethylamines and antidepressants, ADHD medications, and antiretrovirals found very limited pharmacokinetic data; only one case report suggested a possible interaction between 4-FA and ADHD medication. Pharmacodynamic profiles indicate potential interactions between both 4-FA and 2C-B with antidepressants and ADHD medications, primarily involving monoamine oxidases for both substances, with monoamine transporters more specific to 4-FA.